PRNANO is an open access, international society journal, published online only. Articles appear continuously on a rolling basis, then organized into quarterly issues (January, April, July, and October). All content is licensed under the Creative Commons CC BY-NC-SA 4.0 license. The mission of our journal is to promote all practical, rational, and progressive aspects of nanomedicine including theory and practice. Authors are invited to send submissions in basic science, translational, preclinical, and clinical research. PRNANO accepts original manuscripts, as well as replication studies and discussions of negative results as long as they are clearly marked as such and move the field forward. Aim and scope of the journal is to provide a good quality and supportive publishing forum with quick turnaround time for nanomedicine researchers and provide reliable and cutting-edge information to their societies and to libraries without additional cost.
NOTE: We are signatories of the San Francisco Declaration on Research Assessment and we advise against the use of journal-based metrics, such as Journal Impact Factors, as a surrogate measure of the quality of individual research articles, to assess an individual scientist’s contributions, or in hiring, promotion, or funding decisions. We support article-based metrics. There are no APC-s in 2019. In the future, our journal fees (if any) will always reflect realistic costs and will be clearly displayed on our home page. We follow the publication policies of WHO as well as the principles and guidelines of COPE.
Pigs provide a sensitive and quantitative animal model of non-IgE-mediated (pseudoallergic) hypersensitivity reactions (HSRs) caused by liposomes and many other nanoparticulate drugs or drug-carrier nanosystems (nanomedicines). The rapidly arising symptoms, including cardiopulmonary, hemodynamic, hematological, blood chemistry and skin changes, resemble the clinical picture in man undergoing infusion reactions to reactogenic nanoparticles. In addition to summarizing the basic features of the pig CARPA model, the review considers some of the advantages and disadvantages of using the model for preclinical evaluation of nanomedicine safety.
This group does not have any discussions yet.